"Interferon-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
| Descriptor ID |
D016898
|
| MeSH Number(s) |
D12.644.276.374.440.890.250 D12.776.467.374.440.890.250 D23.529.374.440.890.250
|
| Concept/Terms |
Interferon-alpha- Interferon-alpha
- Interferon alpha
- alpha-Interferon
- alpha Interferon
- Interferon, Lymphoblastoid
- Lymphoblastoid Interferon
- Interferon, Lymphoblast
- Lymphoblast Interferon
- Interferon Alfa
- Interferon, alpha
- Interferon, Leukocyte
- Leukocyte Interferon
Interferon alpha-17- Interferon alpha-17
- Interferon alpha 17
- Interferon alpha-T
- Interferon alpha T
- LeIF I
- Interferon alpha-88
- Interferon alpha 88
Interferon alpha-7- Interferon alpha-7
- Interferon alpha 7
- LeIF J
- Interferon alpha-J
- Interferon alpha J
Interferon alpha-5- Interferon alpha-5
- Interferon alpha 5
- Interferon alpha5
- IFN-alpha5
- IFN alpha5
Interferon alpha-2- Interferon alpha-2
- Interferon alpha 2
- Interferon-alpha 2
- Interferon alpha-A
- Interferon alpha A
- LeIF A
- IFN-alpha 2
- IFN-alpha-2
|
Below are MeSH descriptors whose meaning is more general than "Interferon-alpha".
Below are MeSH descriptors whose meaning is more specific than "Interferon-alpha".
This graph shows the total number of publications written about "Interferon-alpha" by people in this website by year, and whether "Interferon-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 2 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 2 | 2 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 2 | 4 |
| 2011 | 3 | 1 | 4 |
| 2012 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon-alpha" by people in Profiles.
-
An Interferon-Induced Digital Vasculitis-Like Syndrome: A Case Report. Am J Ther. 2016 May-Jun; 23(3):e920-5.
-
Anti-cytokine autoantibodies in postherpetic neuralgia. J Transl Med. 2015 Oct 20; 13:333.
-
Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus. 2014 Aug; 23(9):881-8.
-
Gene-expression-guided selection of candidate loci and molecular phenotype analyses enhance genetic discovery in systemic lupus erythematosus. Clin Dev Immunol. 2012; 2012:682018.
-
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012 Jun; 56(6):1276-82.
-
The autoimmune disease risk allele of UBE2L3 in African American patients with systemic lupus erythematosus: a recessive effect upon subphenotypes. J Rheumatol. 2012 Jan; 39(1):73-8.
-
Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-a and serologic autoimmunity in lupus patients. J Immunol. 2011 Aug 01; 187(3):1298-303.
-
Network analysis of associations between serum interferon-a activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011 Apr; 63(4):1044-53.
-
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102.
-
Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8.